Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Exercise test could revolutionize monitoring of rare metabolic muscle disease

NCT ID NCT03802279

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study looked at whether an exercise test can be used to monitor patients with a rare hereditary disease that causes severe muscle breakdown (rhabdomyolysis). Researchers measured heart function and oxygen use during exercise in 27 patients. The goal was to find a reliable way to track disease severity and treatment effects in future clinical trials.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could provide a simple, non-invasive way to monitor disease severity and treatment response in patients with rhabdomyolysis due to hereditary metabolic disorders.
What could go wrong
This is a small, completed observational study with only 27 participants. It does not test a treatment, so it may not directly lead to new therapies. The effort test may not be feasible for all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

27 people

The number who actually took part.

Started

Oct 2019

Finished

Dec 2021

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The population to be studied consists of 40 patients with metabolic rhabdomyolyses followed by the centre of reference for metabolic diseases of the child and adult of the Necker Hospital.

Ages

6 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

subjects with metabolic rhabdomyolysis related to a hereditary metabolic disease : Inclusion Criteria: * pathology characterized on the biochemical and molecular level * patients who can make an effort test * patients who benefited from a diagnostically targeted muscle biopsy with backup of myoblasts (group 1) * patients who have benefited from a diagnostically targeted muscle biopsy but whose myoblasts are not available (group 2) Exclusion Criteria * inability or refusal of compliance to the requirements of the research * patients with contraindications for the effort test in particular heart failure and acute rhabdomyolysis * Patients without biochemical and/or molecular diagnosis Criteria for inclusion of witness patients : * holders of parental authority and/or patients not opposed to the use of their cardio-respiratory analysis results for this study or to the use of their myoblasts for this study * normal cardio-respiratory analysis results * normal myoblasts (group 4).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Rhabdomyolysis linked to A hereditary disease of metabolism are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Hôpital Necker-Enfants Malades

    Paris, 75015, France